Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma

Aim of this prospective multicenter study is to evaluate the safety of an endoscopic follow-up strategy in patients treated with endoscopic resection (ER) for submucosal or high-risk mucosal esophageal adenocarcinoma (T1bN0M0 or HR T1aN0M0 EAC).

Trial Details

NCT ID
NCT03222635
Phase
NA
Sponsor
Amsterdam UMC
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • Endoscopic follow-up
Locations (sample)
  • Sydney, Australia|-33.86785,151.20732
  • Brussels, Belgium|50.85045,4.34878
  • Ghent, Belgium|51.05,3.71667
  • Leuven, Belgium|50.87959,4.70093
  • Roeselare, Belgium|50.94653,3.12269

Key Eligibility Criteria

  • Patients with submucosal or high-risk mucosal EAC diagnosed in an ER specimen, by an expert gastrointestinal (GI) pathologists.
  • Signed informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →